Page 288 - WSAVA2018
P. 288

 25-28 September, 2018 | Singapore
The drug has been limited to use in dogs 12 months
or older, predominantly because in one high-dose safety study, generalized demodicosis developed
in some young laboratory dogs. Oclacitinib has not been evaluated in combination with other drugs
such as systemic corticosteroids or ciclosporin; and concurrent use should be avoided with these drugs.
It can be used safely in conjunction with antibiotics, antihistamines, antifungal drugs, NSAIDs, allergen- specific immunotherapy and vaccination of treated dogs is effective. Oclacitinib does not appear to interfere
with serologic or intradermal allergy tests. As with other immunosuppressive treatments, oclacitinib modulates the immune system and may increase susceptibility
to infection and infestation and exacerbate neoplastic conditions. It is contraindicated in dogs with severe infections, demodicosis, or with active malignancy.
LOKIVETMAB
Lokivetmab (Cytopoint®, Canine Atopic Dermatitis Immunotherapeutic®) is a caninized anti-canine interleukin (IL)-31 monoclonal antibody that binds to and neutralises circulating IL-31, thereby inhibiting its binding to the IL-31 receptor. The subcutaneous administration of lokivetmab results in a dose related reduction in canine IL-31-induced pruritus in dogs for up to eight weeks following a single dose. A blinded placebo controlled trial revealed a greater reduction in pruritus for at
least one month compared to placebo and the level and duration of response was shown to increase with increased dose (Michels 2016). In a clinical trial involving client-owned dogs with atopic dermatitis, a single subcutaneous injection of lokivetmab at a dose of 2 mg/ kg began to reduce pruritus within one day and was effective for a full month for 80% of affected dogs.
Lokivetmab has a good safety profile. Adverse effects are minimal and include vomiting, diarrhea, and lethargy. (Michels 2016). In a field safety study, lokivetmab was well tolerated in dogs after two subcutaneous monthly injections. A wide variety of concomitant medications were safely used, including parasiticides, antibiotics, antifungals, corticosteroids, vaccines, immunotherapy, antihistamines, and other antipruritics, such as oclacitinib and cyclosporin (Michels 2016). Lokivetmab has also been demonstrated to be well tolerated in a laboratory safety study in which seven consecutive monthly subcutaneous injections were administered to laboratory beagle dogs at doses of 3.3 mg/kg or 10 mg/kg body weight (12 dogs per group) (Zoetis data).
REFERENCES
Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, Follis SL, King VL, Boucher JF, Stegemann MR. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary dermatology. 2013 Oct 1;24(5):479.
Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Veterinary dermatology. 2013 Dec 1;24(6):587.
Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Veterinary dermatology 2013; Dec 1;24(1):48–53, e11–12.
Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Veterinary dermatology. 2014 Dec 1;25(6):512.
Krautmann M, Miller W, Walters R, Garcia-Tapia D, King V, Figueiredo J, Hoover D. Long-term laboratory safety study of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody, in normal dogs. Veterinary dermatology. 2016 May 1;27:73-4.
Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Veterinary dermatology. 2015 Feb 1;26(1):23.
Michels GM, Walsh KF, Kryda KA, Mahabir SP, Walters RR, Hoevers JD, Martinon OM. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client- owned dogs with atopic dermatitis. Veterinary dermatology. 2016 Dec 1;27(6):505.
Michels GM, Ramsey D, Walsh K, Martinon O, Mahabir S, Hoevers J, Walters
R, Boucher J, Dunham S. A blinded, randomized, placebo-controlled trial investigating three dose levels of lokivetmab (zts-00103289), a caninized anti- canine Il-31 monoclonal antibody, for the reduction of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary dermatology. 2016 May 1;27:55.
Moyaert H, Van Brussel L, Borowski S, Escalada M, Mahabir SP, Walters RR, Stegemann MR. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Veterinary dermatology. 2017 Dec 1;28(6):593.
  286
43RD WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND 9TH FASAVA CONGRESS










































































   286   287   288   289   290